-+ 0.00%
-+ 0.00%
-+ 0.00%

Lixte reports favorable interim results for LB-100 plus dostarlimab ovarian cancer trial

PUBT·04/13/2026 12:06:23
Listen to the news
Lixte reports favorable interim results for LB-100 plus dostarlimab ovarian cancer trial
  • Lixte Biotechnology reported preliminary results already presented at Society of Gynecological Cancer conference held April 10-13, 2026 in San Juan for a trial combining LB-100 with GSK’s PD-1 drug Dostarlimab in ovarian clear cell carcinoma.
  • Interim readout showed an acceptable safety profile and signs of disease control, supporting continued development of combination regimen.
  • Enrollment reached 21 planned participants, with 20 included in interim efficacy analysis.
  • Program is expanding with an additional 21-patient cohort now enrolling at higher LB-100 exposure to further test activity in patients lacking genetic reduction in PP2A.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604130800PRIMZONEFULLFEED9688034) on April 13, 2026, and is solely responsible for the information contained therein.